Incidence and severity of treatment‐related adverse effects: Nd:YAG laser plus Diprospan plus 5‐FU versus Diprospan plus 5‐FU ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
1 finding from 1 review
7
Studies not reported
Very low
Scar severity ‐ Helium‐Neon (He‐Ne) laser plus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream versus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream ‐ Vancouver Scar scale (VSS) (higher scores... · participants with hypertrophic and keloid scars
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ regrowth ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 1.5 [0.27, 8.22]
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ pain related to treatment ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 3
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ hyperpigmentation ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 5
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ depigmentation ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 1 [0.07, 15.12]
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ purpura ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 15
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ total ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 4.67 [1.53, 14.26]
Studies not reported
Very low
Mortality at 12 months · people living with HIV
It is very uncertain whether rapid antiretroviral therapy (ART) changes mortality at 12 months compared with standard care (very low certainty).
1 finding from 1 review
HIV virological suppression at 6 months (viral load < 400 copies/mL) · people living with HIV
Rapid antiretroviral therapy (ART) probably leads to higher virological suppression at 12 months compared with standard care (moderate certainty).
1 finding from 1 review
Retention in care at 12 months · people living with HIV
Rapid antiretroviral therapy (ART) may leads to higher retention in care at 12 months compared with standard care (low certainty).
1 finding from 1 review
Uptake of ART at 90 days · people living with HIV
Rapid antiretroviral therapy (ART) may leads to higher uptake of ART at 90 days compared with standard care (low certainty).
1 finding from 1 review
Uptake of ART at 12 months · people living with HIV
Rapid antiretroviral therapy (ART) probably leads to higher uptake of ART at 12 months compared with standard care (moderate certainty).
1 finding from 1 review
Treatment modification · people living with HIV
It is very uncertain whether rapid antiretroviral therapy (ART) changes treatment modification compared with standard care (very low certainty).
1 finding from 1 review
Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis
It is very uncertain whether group B cognitive behavioural therapy: cognitive behavioural therapy… changes prodromal symptoms: transition to psychosis Long‐term (events) compared with supportive therapy (very low certainty).
1 finding from 1 review
Global state: clinically important change in global state · people in the prodromal stage of psychosis
1 finding from 1 review
Mental state · people in the prodromal stage of psychosis
1 finding from 1 review
Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis
1 finding from 1 review
Adverse effects: at least one serious adverse event · people in the prodromal stage of psychosis
1 finding from 1 review
Quality of Life Manchester Short Assessment (MANSA) · people in the prodromal stage of psychosis
1 finding from 1 review